175 related articles for article (PubMed ID: 21085965)
1. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.
Jia L; Gorman GS; Coward LU; Noker PE; McCormick D; Horn TL; Harder JB; Muzzio M; Prabhakar B; Ganesh B; Das Gupta TK; Beattie CW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):513-24. PubMed ID: 21085965
[TBL] [Abstract][Full Text] [Related]
2. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.
Warso MA; Richards JM; Mehta D; Christov K; Schaeffer C; Rae Bressler L; Yamada T; Majumdar D; Kennedy SA; Beattie CW; Das Gupta TK
Br J Cancer; 2013 Mar; 108(5):1061-70. PubMed ID: 23449360
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M
Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131
[TBL] [Abstract][Full Text] [Related]
4. p28, a first in class peptide inhibitor of cop1 binding to p53.
Yamada T; Christov K; Shilkaitis A; Bratescu L; Green A; Santini S; Bizzarri AR; Cannistraro S; Gupta TK; Beattie CW
Br J Cancer; 2013 Jun; 108(12):2495-504. PubMed ID: 23736031
[TBL] [Abstract][Full Text] [Related]
5. A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice.
Gorman GS; Coward LU; Freeman L; Noker PE; Beattie CW; Jia L
J Pharm Biomed Anal; 2010 Dec; 53(4):991-6. PubMed ID: 20638810
[TBL] [Abstract][Full Text] [Related]
6. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells.
Yamada T; Mehta RR; Lekmine F; Christov K; King ML; Majumdar D; Shilkaitis A; Green A; Bratescu L; Beattie CW; Das Gupta TK
Mol Cancer Ther; 2009 Oct; 8(10):2947-58. PubMed ID: 19808975
[TBL] [Abstract][Full Text] [Related]
7. Noncationic peptides obtained from azurin preferentially enter cancer cells.
Taylor BN; Mehta RR; Yamada T; Lekmine F; Christov K; Chakrabarty AM; Green A; Bratescu L; Shilkaitis A; Beattie CW; Das Gupta TK
Cancer Res; 2009 Jan; 69(2):537-46. PubMed ID: 19147567
[TBL] [Abstract][Full Text] [Related]
8. Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy.
Bizzarri AR; Santini S; Coppari E; Bucciantini M; Di Agostino S; Yamada T; Beattie CW; Cannistraro S
Int J Nanomedicine; 2011; 6():3011-9. PubMed ID: 22162658
[TBL] [Abstract][Full Text] [Related]
9. Anticancer Actions of Azurin and Its Derived Peptide p28.
Huang F; Shu Q; Qin Z; Tian J; Su Z; Huang Y; Gao M
Protein J; 2020 Apr; 39(2):182-189. PubMed ID: 32180097
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
11. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt.
Mehta RR; Yamada T; Taylor BN; Christov K; King ML; Majumdar D; Lekmine F; Tiruppathi C; Shilkaitis A; Bratescu L; Green A; Beattie CW; Das Gupta TK
Angiogenesis; 2011 Sep; 14(3):355-69. PubMed ID: 21667138
[TBL] [Abstract][Full Text] [Related]
12. Modelling the interaction between the p53 DNA-binding domain and the p28 peptide fragment of Azurin.
Santini S; Bizzarri AR; Cannistraro S
J Mol Recognit; 2011; 24(6):1043-55. PubMed ID: 22038811
[TBL] [Abstract][Full Text] [Related]
13. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
14. A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions.
Mehta RR; Hawthorne M; Peng X; Shilkaitis A; Mehta RG; Beattie CW; Das Gupta TK
Cancer Prev Res (Phila); 2010 Oct; 3(10):1351-60. PubMed ID: 20841487
[TBL] [Abstract][Full Text] [Related]
15. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer.
Yamada T; Goto M; Punj V; Zaborina O; Chen ML; Kimbara K; Majumdar D; Cunningham E; Das Gupta TK; Chakrabarty AM
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14098-103. PubMed ID: 12393814
[TBL] [Abstract][Full Text] [Related]
16. A nanotechnological, molecular-modeling, and immunological approach to study the interaction of the anti-tumorigenic peptide p28 with the p53 family of proteins.
Coppari E; Yamada T; Bizzarri AR; Beattie CW; Cannistraro S
Int J Nanomedicine; 2014; 9():1799-813. PubMed ID: 24748790
[TBL] [Abstract][Full Text] [Related]
17. Polymeric nanoparticle-docetaxel for the treatment of advanced solid tumors: phase I clinical trial and preclinical data from an orthotopic pancreatic cancer model.
Song SY; Kim KP; Jeong SY; Park J; Park J; Jung J; Chung HK; Lee SW; Seo MH; Lee JS; Jung KH; Choi EK
Oncotarget; 2016 Nov; 7(47):77348-77357. PubMed ID: 27764799
[TBL] [Abstract][Full Text] [Related]
18. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
[TBL] [Abstract][Full Text] [Related]
19. p28 Bacterial Peptide, as an Anticancer Agent.
Yaghoubi A; Khazaei M; Avan A; Hasanian SM; Cho WC; Soleimanpour S
Front Oncol; 2020; 10():1303. PubMed ID: 32850408
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies.
Schwartsmann G; DiLeone LP; Horowitz M; Schunemann D; Cancella A; Pereira AS; Richter M; Souza F; da Rocha AB; Souza FH; Pohlmann P; De Nucci G
Invest New Drugs; 2006 Sep; 24(5):403-12. PubMed ID: 16505950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
